TY - JOUR
T1 - Cord blood transplantation for AML
T2 - Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study
AU - Baron, Frédéric
AU - Nagler, Arnon
AU - Galimard, Jacques-Emmanuel
AU - Sanz, Jaime
AU - Versluis, Jurjen
AU - Forcade, Edouard
AU - Chevallier, Patrice
AU - Sirvent, Anne
AU - Anthias, Chloe
AU - Kuball, Jürgen
AU - Furst, Sabine
AU - Rambaldi, Alessandro
AU - Sierra, Jorge
AU - von dem Borne, Peter A
AU - Gallego Hernanz, Maria Pilar
AU - Cluzeau, Thomas
AU - Robinson, Stephen
AU - Raiola, Anna Maria
AU - Labussière-Wallet, Hélène
AU - Byrne, Jenny L
AU - Malfuson, Jean-Valère
AU - Ruggeri, Annalisa
AU - Mohty, Mohamad
AU - Ciceri, Fabio
N1 - Publisher Copyright:
© 2023 British Society for Haematology and John Wiley & Sons Ltd.
PY - 2024/1
Y1 - 2024/1
N2 - We investigated whether secondary versus de novo acute myeloid leukaemia (AML) would be associated with poor outcomes in adult acute AML patients in first complete remission (CR1) receiving unrelated cord blood transplantation (CBT). This is a retrospective study from the acute leukaemia working party of the European Society for Blood and Marrow Transplantation. Inclusion criteria included adult at first allogeneic haematopoietic cell transplantation between 2000 and 2021, unrelated single or double unit CBT, AML in CR1, no ex vivo T-cell depletion and no post-transplant cyclophosphamide. The primary end-point of the study was leukaemia-free survival (LFS). A total of 879 patients with de novo (n = 696) or secondary (n = 183) AML met the inclusion criteria. In multivariable analyses, sAML patients had non-significantly different LFS (HR = 0.98, p = 0.86), overall survival (HR = 1.07, p = 0.58), relapse incidence (HR = 0.74, p = 0.09) and non-relapse mortality (HR = 1.26, p = 0.13) than those with de novo AML. Our results demonstrate non-significantly different LFS following CBT in adult patients with secondary versus de novo AML.
AB - We investigated whether secondary versus de novo acute myeloid leukaemia (AML) would be associated with poor outcomes in adult acute AML patients in first complete remission (CR1) receiving unrelated cord blood transplantation (CBT). This is a retrospective study from the acute leukaemia working party of the European Society for Blood and Marrow Transplantation. Inclusion criteria included adult at first allogeneic haematopoietic cell transplantation between 2000 and 2021, unrelated single or double unit CBT, AML in CR1, no ex vivo T-cell depletion and no post-transplant cyclophosphamide. The primary end-point of the study was leukaemia-free survival (LFS). A total of 879 patients with de novo (n = 696) or secondary (n = 183) AML met the inclusion criteria. In multivariable analyses, sAML patients had non-significantly different LFS (HR = 0.98, p = 0.86), overall survival (HR = 1.07, p = 0.58), relapse incidence (HR = 0.74, p = 0.09) and non-relapse mortality (HR = 1.26, p = 0.13) than those with de novo AML. Our results demonstrate non-significantly different LFS following CBT in adult patients with secondary versus de novo AML.
KW - acute myeloid leukaemia
KW - AML
KW - cord blood transplantation
KW - de novo
KW - secondary
UR - http://www.scopus.com/inward/record.url?scp=85173459626&partnerID=8YFLogxK
U2 - 10.1111/bjh.19130
DO - 10.1111/bjh.19130
M3 - Article
C2 - 37784256
SN - 0007-1048
VL - 204
SP - 250
EP - 259
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -